Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Rice

Showing results (231-240 of 238) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 238 results.
Cancer Immunology, Immunotherapy : CII|March 9, 2021
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2020
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung CancerTina Cascone, Boris Sepesi, Heather Y Lin, et al.
Annals of Surgical Oncology|March 18, 2026
ASO Visual Abstract: Patient-Reported Symptom Recovery After Upper Gastrointestinal Cancer Surgery: A Prospective Study Using the MDASI-UGI-SurgKoichi Tomita, Paula M Smith, Maho Takayama, et al.
Annals of Surgical Oncology|February 19, 2026
Patient-Reported Symptom Recovery After Upper Gastrointestinal Cancer Surgery: A Prospective Study Using the MDASI-UGI-SurgKoichi Tomita, Paula M Smith, Maho Takayama, et al.
Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Pageof 24

Showing results (231-240 of 238) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 238 results.
Cancer Immunology, Immunotherapy : CII|March 9, 2021
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2020
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung CancerTina Cascone, Boris Sepesi, Heather Y Lin, et al.
Annals of Surgical Oncology|March 18, 2026
ASO Visual Abstract: Patient-Reported Symptom Recovery After Upper Gastrointestinal Cancer Surgery: A Prospective Study Using the MDASI-UGI-SurgKoichi Tomita, Paula M Smith, Maho Takayama, et al.
Annals of Surgical Oncology|February 19, 2026
Patient-Reported Symptom Recovery After Upper Gastrointestinal Cancer Surgery: A Prospective Study Using the MDASI-UGI-SurgKoichi Tomita, Paula M Smith, Maho Takayama, et al.
Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Pageof 24